



## Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX<sup>®</sup> mesalamine. [Corrigendum]

Nanda K, Moss AC. *Clinical Pharmacology: Advances and Applications*. 2012, 4:41–50.

The authors apologize for errors on Tables 1, 2, and 3.

### Table 1

Citation 40, Hussain et al, should have been citation 44, Shire US Inc.

### Table 2

Lichtenstein et al data, the confidence interval (CI) of the odds ratio for achieving remission with MMX mesalamine 1.2 g twice daily (1.44–8.41) should be listed as a 97.5% CI rather than a 95% CI.

### Table 3

Prantera et al, the MMX mesalamine 2.4 g once daily cohort should have an N value of 156, not 162, and the 12-month relapse rate should be 25.0%, not 15.0%.

Pramtera et al, the Asacol 2.4 g once daily cohort should be labeled “Asacol 2.4 g/day twice daily”, and should have an N value of 167, not 156.

Kane et al, the N value should be 194, not 167.